Jenna Vo
Psychiatric/Mental Health · Kent, WANPI 1699448969
Payments from drug & device makers
Across 832 payments — averaging $21.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- AbbVie$2K
- Neurocrine Biosciences, Inc.$1K
- Alkermes, Inc.$1K
- Johnson & Johnson$1K
- plus $8K from 23 others
What the payments were for
- Food & beverage$17,34199%
- Education$2351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 93 | $2,074 |
| Otsuka America Pharmaceutical, Inc. | 76 | $1,862 |
| AbbVie | 88 | $1,841 |
| Neurocrine Biosciences, Inc. | 56 | $1,393 |
| Alkermes, Inc. | 59 | $1,346 |
| Johnson & Johnson | 50 | $1,323 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 82 | $1,276 |
| Lundbeck LLC | 67 | $1,096 |
| Corium, LLC | 33 | $784 |
| Axsome Therapeutics, Inc. | 36 | $780 |
| Ironshore Pharmaceuticals Inc. | 38 | $585 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $489 |
| Almatica Pharma LLC | 25 | $476 |
| Indivior Inc. | 28 | $422 |
| Acadia Pharmaceuticals Inc | 8 | $420 |
| Vanda Pharmaceuticals Inc. | 17 | $401 |
| Sunovion Pharmaceuticals Inc. | 10 | $275 |
| Collegium Pharmaceutical, Inc. | 10 | $149 |
| Supernus Pharmaceuticals, Inc. | 6 | $134 |
| Eisai Inc. | 1 | $125 |
| Idorsia Pharmaceuticals US Inc | 4 | $73 |
| Braeburn Inc. | 3 | $63 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Biogen | 2 | $40 |
| Janssen Scientific Affairs, LLC | 1 | $39 |
| Adlon Therapeutics L.p. | 1 | $24 |
| Tris Pharma Inc | 1 | $20 |
| Noven Therapeutics, LLC | 1 | $19 |
| Brainsway USA Inc | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$715
- LYBALVI$460
- VRAYLAR$371
- UZEDY$236
- INGREZZA$234
- CAPLYTA$129
- Dayvigo$125
- INVEGA SUSTENNA$124
- INVEGA TRINZA$124
- AUSTEDO$123
- Auvelity$121
- ABILIFY MAINTENA$121
- NUPLAZID$118
- Azstarys$112
How this compares
$17,576 in reported general payments places this provider in the 95th percentile of 931 psychiatric/mental health providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 50 | $565,945 |
| IngrezzaValbenazine Tosylate | 24 | $225,412 |
| AristadaAripiprazole Lauroxil | 53 | $183,489 |
| RexultiBrexpiprazole | 44 | $114,937 |
| TrintellixVortioxetine Hydrobromide | 54 | $45,379 |
| VraylarCariprazine Hcl | 16 | $35,050 |
| CaplytaLumateperone Tosylate | 18 | $30,031 |
| Jornay PmMethylphenidate Hcl | 16 | $7,465 |
| Aripiprazole | 32 | $2,231 |
| Memantine Hcl | 15 | $2,030 |
| Olanzapine OdtOlanzapine | 13 | $1,896 |
| Divalproex Sodium ErDivalproex Sodium | 19 | $1,492 |
| Mirtazapine | 99 | $1,467 |
| Olanzapine | 33 | $1,210 |
| Bupropion XlBupropion Hcl | 37 | $1,116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $2,074 | $565,94550 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,393 | $225,41224 claims |
| Alkermes, Inc.Aristada | $1,346 | $183,48953 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,862 | $114,93744 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $489 | $45,37954 claims |
| AbbVieVraylar | $1,841 | $35,05016 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,276 | $30,03118 claims |
| Ironshore Pharmaceuticals Inc.Jornay Pm | $585 | $7,46516 claims |
| Almatica Pharma LLCSertraline Hcl | $476 | $33246 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 931 psychiatric/mental health providers in Washington.
Other psychiatric/mental health in Kent
- Agnes MarambaKent$14K
- Angela CombsRichland$121K
- Ashley McGinnisAuburn$26K
- Courtney YantPuyallup$26K
- Dawn MasonSpokane$25K
- Janine TorresAuburn$24K
- Jennifer WilsonYakima$23K
- Patricia MorganKirkland$21K
- Kojo SarfoEllensburg$20K
- Brendan RoeVancouver$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.